Erectile dysfunction medications and skin cancer: An analysis in US Veterans
Urology Feb 10, 2019
Christie A, et al. - Using the Department of Veterans Affairs Informatics and Computing Infrastructure database (VINCI), researchers estimated the correlation between phosphodiesterase 5 inhibitor drugs (PDE5i) and skin cancer among 2.55 million Veterans. The mean age of the PDE5i group and non-PDE5i group was 59.2 years (SD±10.8) and 58.7 (SD± 10.8), respectively whereas mean follow-up time for the PDE5i group was 8.9 years (SD± 4.2) and 8.5 years (SD± 4.3) for non-PDE5i group. They noticed an insignificant raised risk of malignant melanoma and a greater risk of basal cell carcinoma among Veterans using PDE5is as compared to non-PDE5i users. They recorded more mean outpatient visits/year (8.9 SD+/- 9.50) in PDE5i users than non-PDE5i users (5.9 SD +/-10.0). Overall, they suggested PDE5i drug, a reliable therapy for erectile dysfunction.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins